Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C2306H3594N610O694S26
Dược Lực Học :
Interferes with lymphocyte activation by specifically binding to the lymphocyte antigen, CD2, and inhibiting LFA-3/CD2 interaction. Activation of T lymphocytes involving the interaction between LFA-3 on antigen-presenting cells and CD2 on T lymphocytes plays a role in the pathophysiology of chronic plaque psoriasis. Also causes a reduction in subsets of CD2+ T lymphocytes as well as CD4+ and CD8+ T lymphocytes.
Cơ Chế Tác Dụng :
Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD.
Inhibits T-lymphocyte activation and production by binding to the CD2 lymphocyte antigen.
Dược Động Học :
▧ Absorption :
Bioavailability after IM administration is 63%.
▧ Half Life :
~270 hours
Độc Tính :
While it has been found to cross the placenta in monkeys, it is not yet known if it also diffuses into breast milk.
Chỉ Định :
As an immunosuppressive drug, Alefacept can be used for treatment of moderate to severe chronic plaque psoriasis
Tương Tác Thuốc :
-
Canakinumab
Increases immunosuppressive effects and risk of infection.
-
Rilonacept
results in increased immunosuppressive effects; increases the risk of infection.
Liều Lượng & Cách Dùng :
Powder, for solution - Intramuscular